[go: up one dir, main page]

US20020198391A1 - Method for the preparation of citalopram - Google Patents

Method for the preparation of citalopram Download PDF

Info

Publication number
US20020198391A1
US20020198391A1 US10/186,337 US18633702A US2002198391A1 US 20020198391 A1 US20020198391 A1 US 20020198391A1 US 18633702 A US18633702 A US 18633702A US 2002198391 A1 US2002198391 A1 US 2002198391A1
Authority
US
United States
Prior art keywords
reaction
pph
isobenzofuran
nacn
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/186,337
Inventor
Hans Petersen
Michael Rock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Assigned to H. LUNDBECK A/S reassignment H. LUNDBECK A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROCK, MICHAEL HAROLD, PETERSEN, HANS
Publication of US20020198391A1 publication Critical patent/US20020198391A1/en
Priority to US11/285,922 priority Critical patent/US7271273B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44Palladium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/74Iron group metals
    • B01J23/755Nickel

Definitions

  • the present invention relates to a method for the preparation of key intermediates in the process for the preparation of the well known antidepressant drug citalopram, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile.
  • Citalopram is a well known antidepressant drug that has now been on the market for some years and has the following structure:
  • Citalopram can be prepared by several disclosed methods. A method and an intermediate for the preparation of citalopram were described in U.S. Pat. No 4,650,884. Commercially useful processes are disclosed in International patent application Nos. WO 98019511, WO 98019512 and WO 98019513.
  • this key intermediate may be obtained in a high yield as a very pure product by a new catalytic process in which a halogen or a group of the general formula CF 3 —(CF 2 ) n —SO 2 — wherein n is any suitable whole number between 0 and 4, situated in the 5-position of a 3-H-isobenzofuran-1-one, is exchanged with a cyanide group.
  • the key intermediate is then subjected to two successive Grignard reactions, i.e. with 4-fluorophenyl magnesium halogenide and N.N-dimethylaminopropyl magnesium halogenide, respectively, whereby citalopram is obtained.
  • the present invention relates to a novel method for the preparation of an intermediate in the preparation of citalopram comprising reacting a compound of Formula IV
  • R′ is Cl, Br, I or a group of the formula CF 3 —(CF 2 ) n —SO 2 —, wherein n is 0-4, with a cyanide source in the presence or absence of a catalyst, whereby 5-cyano-isobenzofuran-1-one is obtained.
  • This intermediate product can be further reacted to citalopram as described above.
  • reaction of IV to 5-cyanophtalide may be carried out in more convenient solvents, at a low temperature and at a minimal excess of CN ⁇ .
  • the process has environmental advantages in that it only uses small amounts of heavy metals.
  • the cyano sources may conveniently be selected from a group consisting of cyanide sources such as (R′′ 4 N)CN wherein each R′′ represents C 1-8 -alkyl optionally two R′′ together with the nitrogen form a ring structure; NaCN, KCN, Zn(CN) 2 or Cu(CN).
  • the reaction of the present invention is performed in the presence or absence of a catalyst.
  • the catalysts are i.e. Ni (0), Pd(0) or Pd(II) catalysts as described by Sakakibara et. al. in Bull. Chem. Soc. Jpn., 61, 1985-1990, (1988).
  • Preferred catalysts are Ni(PPh 3 ) 3 or Pd(PPh 3 ) 4 , or Pd(PPh) 2 Cl 2 .
  • a Nickel(0) complex is prepared in situ before the cyanide exchange reaction by reduction of a Nickel(II) precursor such as NiCl 2 or NiBr 2 by a metal, such as zinc, magnesium or mangan in the presence of excess of complex ligands, preferably triphenylphosphin.
  • a Nickel(II) precursor such as NiCl 2 or NiBr 2
  • a metal such as zinc, magnesium or mangan in the presence of excess of complex ligands, preferably triphenylphosphin.
  • the Pd or Ni-catalyst is conveniently used in an amount of 0.5-10, preferably 2-6, most preferably about 4-5 mol %.
  • Cu + and Zn 2+ may be added to the reaction mixture in substoichiometric amounts and may function as recycleable cyanide sources, which receives the cyanide from other cyanide sources such as NaCN or KCN.
  • Substoichiometric amounts of Cu + and Zn 2+ respectively, means 1-20%, preferably 5-10%.
  • the reactions may be performed in any convenient solvent as described in Sakakibara et. al. in Bull. Chem. Soc. Jpn., 61, 1985-1990, (1988).
  • Preferred solvents are acetonitrile, ethylacetate, THF, DMF or NMP;
  • a compound of Formula IV wherein R is Cl is reacted with NaCN in the presence of a Ni(PPh 3 ) 3 which is preferably prepared in situ as described above.
  • a compound of formula IV, wherein R is Br or I is reacted with KCN, NaCN, CuCN or Zn(CN) 2 in the presence of Pd(PPh 3 ) 4 .
  • substoichiometric amounts of Cu(CN) and Zn(CN) 2 are added as recycleable cyanide sources.
  • the Cu(CN) is the cyanide source and without catalyst.
  • the reaction is performed at elevated temperature.
  • the reaction is performed as a neat reaction i.e. without added solvent.
  • the reaction is performed in an ionic liquid of the general formula R 4 N + , X ⁇ , wherein R are alkyl-groups or two of the R groups together form an ring and X ⁇ is the counterion.
  • R 4 N + X ⁇ represents
  • the reaction is conducted with apolar solvents such as benzene, xylene or mesitylene and under the influence of microwaves by using i.e. Synthewave 1000TM by Prolabo.
  • the reaction is performed without added solvent.
  • the temperature ranges are dependent upon the reaction type. If no catalyst is present preferred temperatures are in the range of 100-200° C. However, when the reaction is conducted under the influence of microwaves the temperature in the reaction mixture may raise to above 300° C. More preferred temperature ranges are between 120-170° C. The most preferred range is 130-150° C.
  • the preferred temperature range is between 0 and 100° C. More preferred are temperature ranges of 40-90° C. Most preferred temperature ranges are between 60-90° C.
  • reaction conditions are conventional conditions for such reactions and may easily be determined by a person skilled in the art.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a new and improved method for the preparation of 5-cyano-phtalid, which is a key intermediate in the preparation of the antidepressant compound citalopram.

Description

  • This application is a continuation of International application no. PCT/DK99/00740, filed Dec. 30, 1999. The disclosure of the prior application is hereby incorporated by reference.[0001]
  • The present invention relates to a method for the preparation of key intermediates in the process for the preparation of the well known antidepressant drug citalopram, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile. [0002]
  • BACKGROUND OF THE INVENTION
  • Citalopram is a well known antidepressant drug that has now been on the market for some years and has the following structure: [0003]
    Figure US20020198391A1-20021226-C00001
  • It is a selective, centrally acting serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor, accordingly having antidepressant activities. The antidepressant activity of the compound has been reported in several publications, eg. J. Hyttel, [0004] Prog Neuro-Psychopharmacol. & Biol. Psychiat., 1982, 6, 277-295 and A. Gravem, Acta Psychiatr. Scand., 1987, 75, 478-486. The compound has further been disclosed to show effects in the treatment of dementia and cerebrovascular disorders, EP-A 474580.
  • Citalopram can be prepared by several disclosed methods. A method and an intermediate for the preparation of citalopram were described in U.S. Pat. No 4,650,884. Commercially useful processes are disclosed in International patent application Nos. WO 98019511, WO 98019512 and WO 98019513. [0005]
  • With respect to the above methods for the preparation of citalopram, the process comprising exchange of the 5-bromo group with cyano proved not to be very convenient in commercial scale, since the yield was rather low, the product was impure and, in particular, since it was difficult to separate the resulting citalopram from the corresponding 5-bromo compound. [0006]
  • It has now been found that in a new process for the preparation of citalopram, this key intermediate may be obtained in a high yield as a very pure product by a new catalytic process in which a halogen or a group of the general formula CF[0007] 3—(CF2)n—SO2— wherein n is any suitable whole number between 0 and 4, situated in the 5-position of a 3-H-isobenzofuran-1-one, is exchanged with a cyanide group. By obtaining the correct cyanide substitution at an early stage of the citalopram synthesis, the extensive work up of the old cyanide exchange processes of the previous described processes is avoided. The intermediates of the presently described process are easily purified and obtained in very high yields. The key intermediate is then subjected to two successive Grignard reactions, i.e. with 4-fluorophenyl magnesium halogenide and N.N-dimethylaminopropyl magnesium halogenide, respectively, whereby citalopram is obtained.
  • The preparation of the key intermediate of the invention is described earlier in J.Chem. Soc., 1931, 867 and by Tiroflet, J. in Bull. Soc. Sci. Betagne, 26, 35, 1951. The process for preparation of the compound is a three step synthesis starting from 5-nitro-phtalimide with low yields, especially in the last step of the synthesis. [0008]
  • SUMMARY OF THE INVENTION
  • Accordingly, the present invention relates to a novel method for the preparation of an intermediate in the preparation of citalopram comprising reacting a compound of Formula IV [0009]
    Figure US20020198391A1-20021226-C00002
  • wherein R′ is Cl, Br, I or a group of the formula CF[0010] 3—(CF2)n—SO2—, wherein n is 0-4, with a cyanide source in the presence or absence of a catalyst, whereby 5-cyano-isobenzofuran-1-one is obtained. This intermediate product can be further reacted to citalopram as described above.
  • The reaction of IV to 5-cyanophtalide may be carried out in more convenient solvents, at a low temperature and at a minimal excess of CN[0011] . The process has environmental advantages in that it only uses small amounts of heavy metals.
  • The cyano sources may conveniently be selected from a group consisting of cyanide sources such as (R″[0012] 4N)CN wherein each R″ represents C1-8-alkyl optionally two R″ together with the nitrogen form a ring structure; NaCN, KCN, Zn(CN)2 or Cu(CN).
  • The reaction of the present invention is performed in the presence or absence of a catalyst. The catalysts are i.e. Ni (0), Pd(0) or Pd(II) catalysts as described by Sakakibara et. al. in [0013] Bull. Chem. Soc. Jpn., 61, 1985-1990, (1988). Preferred catalysts are Ni(PPh3)3 or Pd(PPh3)4, or Pd(PPh)2Cl2.
  • In a particularly preferred embodiment, a Nickel(0) complex is prepared in situ before the cyanide exchange reaction by reduction of a Nickel(II) precursor such as NiCl[0014] 2 or NiBr2 by a metal, such as zinc, magnesium or mangan in the presence of excess of complex ligands, preferably triphenylphosphin.
  • The Pd or Ni-catalyst is conveniently used in an amount of 0.5-10, preferably 2-6, most preferably about 4-5 mol %. [0015]
  • Cu[0016] + and Zn2+ may be added to the reaction mixture in substoichiometric amounts and may function as recycleable cyanide sources, which receives the cyanide from other cyanide sources such as NaCN or KCN. Substoichiometric amounts of Cu+ and Zn2+, respectively, means 1-20%, preferably 5-10%.
  • The reactions may be performed in any convenient solvent as described in Sakakibara et. al. in [0017] Bull. Chem. Soc. Jpn., 61, 1985-1990, (1988). Preferred solvents are acetonitrile, ethylacetate, THF, DMF or NMP;
  • In one aspect of the invention, a compound of Formula IV wherein R is Cl is reacted with NaCN in the presence of a Ni(PPh[0018] 3)3 which is preferably prepared in situ as described above.
  • In another aspect of the invention, a compound of formula IV, wherein R is Br or I, is reacted with KCN, NaCN, CuCN or Zn(CN)[0019] 2 in the presence of Pd(PPh3)4. In a particular aspect of the invention, substoichiometric amounts of Cu(CN) and Zn(CN)2 are added as recycleable cyanide sources.
  • In another aspect of same invention, the Cu(CN) is the cyanide source and without catalyst. In a preferred embodiment of this invention, the reaction is performed at elevated temperature. [0020]
  • In a particular aspect of this invention, the reaction is performed as a neat reaction i.e. without added solvent. [0021]
  • In another aspect of the invention, the reaction is performed in an ionic liquid of the general formula R[0022] 4N+, X, wherein R are alkyl-groups or two of the R groups together form an ring and X is the counterion. In one embodiment of the invention, R4N+X represents
    Figure US20020198391A1-20021226-C00003
  • In another particular aspect of this invention, the reaction is conducted with apolar solvents such as benzene, xylene or mesitylene and under the influence of microwaves by using i.e. Synthewave 1000™ by Prolabo. In a particular aspect of this invention, the reaction is performed without added solvent. [0023]
  • The temperature ranges are dependent upon the reaction type. If no catalyst is present preferred temperatures are in the range of 100-200° C. However, when the reaction is conducted under the influence of microwaves the temperature in the reaction mixture may raise to above 300° C. More preferred temperature ranges are between 120-170° C. The most preferred range is 130-150° C. [0024]
  • If catalyst is present, the preferred temperature range is between 0 and 100° C. More preferred are temperature ranges of 40-90° C. Most preferred temperature ranges are between 60-90° C. [0025]
  • Other reaction conditions, solvents, etc. are conventional conditions for such reactions and may easily be determined by a person skilled in the art. [0026]
  • EXAMPLES
  • The invention is further illustrated by the following examples. [0027]
  • Experimental Example 1
  • [0028]
    Figure US20020198391A1-20021226-C00004
  • A mixture of Zn(CN)[0029] 2 (2.4 g, 0.02 mol) and 5-bromo-3H-isobenzofuran-1-one (4.2 g, 0.02 mol) in DMF (80 mL) were stirred at room temperature under an atmosphere of argon for 30 minutes. Then dissolved oxygen was removed by bubbling argon through the reaction mixture for 10 minutes before the addition of tetrakis(triphenylphosphine)palladium (0) (1.2 g, 0.00096 mol,). Then the reaction was heated at 75° C. for 3 hrs, and then the solvent was removed under reduce pressure and the residue poured into water (150 mL). Filtration and followed by drying in vacuo give the crude 5-cyano-3H-isobenzofuran-1-one (2.8 g) (HPLC 95%). An analytical sample was obtained by recrystalisation from acetic acid.
  • Example 2
  • A mixture of Zn(CN)[0030] 2 (0.3 g, 0.00256 mol), NaCN (1 g, 0,02 mol) and 5-bromo-3H-isobenzofuran-1-one (4.2 g, 0.02 mol) in DMF (80 mL) were stirred at room temperature under an atmosphere of argon for 30 minutes. Then dissolved oxygen was removed by bubbling argon through the reaction mixture for 10 minutes before the addition of tetrakis(triphenylphosphine)palladium (0) (1.2 g, 0.00096 mol). Then the reaction was heated at 75° C. for 3 hrs, and then the solvent was removed under reduce pressure and the residue poured into water (150 mL). Filtration and followed by drying in vacuo give the crude 5-cyano-3H-isobenzofuran-1-one (2.7 g) (HPLC 94%). An analytical sample was obtained by recrystalisation from acetic acid.
  • Example 3
  • A mixture of 5-bromo-3H-isobenzofuran-1-one (4.2 g, 0.02 mol) and Cu(CN)[0031] 2 (2.3 g, 0.02 mol) in NMP (60 mL) were stirred at 140° C. for 3hrs. Then solvent was removed by distilation under reduced pressure and the residue was refluxed in water (150 mL) for 10 minutes and allowed to cool to room temperature. Filtration and followed by drying in vacuo give the crude 5-cyano-3H-isobenzofuran-1-one (2.1 g) (HPLC 97%). An analytical sample was obtained by recrystalisation from acetic acid.
    Figure US20020198391A1-20021226-C00005
  • Example 4
  • A mixture of Zn(CN)[0032] 2 (2.4 g, 0.02 mol) and 5-iodo-3H-isobenzofuran-1-one (5.24 g, 0.02 mol) in DMF (80 mL) were stirred at room temperature under an atmosphere of argon for 30 minutes. Then dissolved oxygen was removed by bubbling argon through the reaction mixture for 10 minutes before the addition of tetrakis(triphenylphosphine)palladium (0) (1.2 g, 0.00096 mol). Then the reaction was heated at 75° C. for 3 hrs, and then the solvent was removed under reduce pressure and the residue poured into water (150 mL). Filtration and followed by drying in vacuo give the crude 5-cyano-3H-isobenzofuran-1-one (2.4 g) (HPLC 93%). An analytical sample was obtained by recrystalisation from acetic acid.
    Figure US20020198391A1-20021226-C00006
  • Example 5
  • Under a nitrogen atmosphere, a mixture of NiCl[0033] 2 (0.2 g, 0.0015 mol) and triphenylphosphine (1.6 g, 0.0061 mol) in acetonitrile (80 ml)was heated at reflux for 45 minutes. After cooling to room temperature, zinic powder was added (0.39 g, 0.006 mol) at stirred for 15 minutes before a solution of 5-chloro-3H-isobenzofuran-1-one (3.4 g, 0.02 mol) in THF (40 mL) was added. After stirring for a further 10 minutes, NaCN (1.1 g, 0.021 mol) was added and the reaction heated at 70° C. for 3 hrs, cooled, diluted with acetonitrile (50 mL), and then filtered through celite. The filtrate was concentrated under reduced pressure and the residue was refluxed in water (150 mL) for 10 minutes and allowed to cool to room temperature. Filtration and followed by drying in vacuo give the crude 5-cyano-3H-isobenzofuran-1-one (2.5 g). An analytical sample was obtained by recrystalisation from acetic acid.

Claims (14)

1. A method for the preparation of a compound of the formula
Figure US20020198391A1-20021226-C00007
comprising reacting an isobenzofuran-1-one of the formula
Figure US20020198391A1-20021226-C00008
wherein R′ is a halogen or CF3—(CF2)n—SO2—, wherein n is 0-7, with a cyanide source optionally in the presence of a catalyst.
2. The process of claim 1 wherein R′ is Cl, Br or I.
3. The process of claim 1 wherein R′ is CF3—(CF2)n—SO2—, wherein n is 0, 1,2,3 or 4.
4. The process of claim 1, wherein the cyanide source is selected from (R″4N)CN wherein each R″ is C1-8-alkyl, optionally two R″ together with the nitrogen form a ring structure; KCN, NaCN, Zn(CN)2 or CuCN or combinations thereof.
5. The process of claim 1, wherein Zn2+ or Cu+ are added in substoichiometric amounts in combination with another cyanide source.
6. The process of claim 1, wherein the catalyst is selected from Ni(PPh3)3, Pd(PPh3)4, Pd(dba)3 or Pd(PPh)2Cl2.
7. The process of claim 1, wherein a 5-chloro-isobenzofuran-1-one is subjected to NaCN in the presence of Ni-catalyst.
8. The process of claim 7 wherein the Ni-catalyst is Ni(PPh3)3 prepared in situ by subjecting NiCl2 to a reducing agent, in the presence of PPh3.
9. The process of claim 8 wherein the reducing agent is Zn.
10. The process of claim 1, wherein a 5-bromo- or 5-iodo-isobenzofuran-1-one is subjected to KCN, NaCN, Zn(CN)2, or CuCN or combinations thereof in the presence of Pd(PPh3)4.
11. The process according to claim 1, 2 and 4 wherein a 5-bromo- or 5-iodo-isobenzofuran-1-one is subjected to KCN, NaCN, Zn(CN)2, or CuCN or combinations thereof and the process is performed without catalysts.
12. The process of claim 10 wherein the reaction is performed in an ionic liquid of the general formula R4N+X wherein each R represents C1-8-alkyl optionally two R″ together with the nitrogen form a ring.
13. The process of claim 10 wherein the reaction is performed under the influence of microwaves in an apolar solvent.
14. The process according to claim 10 or claim 12 wherein the reaction is performed as a neat reaction.
US10/186,337 1999-12-30 2002-06-27 Method for the preparation of citalopram Abandoned US20020198391A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/285,922 US7271273B2 (en) 1999-12-30 2005-11-23 Method for the preparation of citalopram

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DK1999/000740 WO2001049672A1 (en) 1999-12-30 1999-12-30 Method for the preparation of citalopram

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1999/000740 Continuation WO2001049672A1 (en) 1999-12-30 1999-12-30 Method for the preparation of citalopram

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/285,922 Division US7271273B2 (en) 1999-12-30 2005-11-23 Method for the preparation of citalopram

Publications (1)

Publication Number Publication Date
US20020198391A1 true US20020198391A1 (en) 2002-12-26

Family

ID=8157174

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/186,337 Abandoned US20020198391A1 (en) 1999-12-30 2002-06-27 Method for the preparation of citalopram
US11/285,922 Expired - Fee Related US7271273B2 (en) 1999-12-30 2005-11-23 Method for the preparation of citalopram

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/285,922 Expired - Fee Related US7271273B2 (en) 1999-12-30 2005-11-23 Method for the preparation of citalopram

Country Status (28)

Country Link
US (2) US20020198391A1 (en)
EP (1) EP1246813B1 (en)
JP (1) JP2003519218A (en)
KR (1) KR100653141B1 (en)
CN (1) CN1211377C (en)
AT (1) ATE253568T1 (en)
AU (1) AU1858400A (en)
BR (1) BR9917604A (en)
CA (1) CA2395733C (en)
CZ (1) CZ20022627A3 (en)
DE (1) DE69912652T2 (en)
DK (1) DK1246813T3 (en)
EA (1) EA004055B1 (en)
ES (1) ES2207312T3 (en)
HK (1) HK1052512B (en)
HR (1) HRP20020633A2 (en)
HU (1) HUP0203840A3 (en)
IL (2) IL150367A0 (en)
IS (1) IS2167B (en)
MX (1) MXPA02006504A (en)
NO (1) NO328359B1 (en)
PL (1) PL198803B1 (en)
PT (1) PT1246813E (en)
SI (1) SI1246813T1 (en)
SK (1) SK11052002A3 (en)
TR (1) TR200201688T2 (en)
UA (1) UA73336C2 (en)
WO (1) WO2001049672A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660873B2 (en) 2000-05-12 2003-12-09 H. Lundbeck A/S Method for the preparation of citalopram
US6768011B2 (en) 2000-03-03 2004-07-27 H. Lundbeck A/S Method for the preparation of citalopram
US20050020670A1 (en) * 2000-03-13 2005-01-27 H. Lundbeck A/S Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofuran
US6849749B2 (en) 1999-04-14 2005-02-01 H. Lundbeck A/S Method for the preparation of citalopram
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69915713T2 (en) 1999-12-28 2005-03-03 H. Lundbeck A/S PROCESS FOR THE PREPARATION OF CITALOPRAM
SK286879B6 (en) 2000-01-14 2009-07-06 H. Lundbeck A/S Method for the preparation of 5-cyanophthalide
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
NL1017500C1 (en) 2000-03-13 2001-04-26 Lundbeck & Co As H Process for the preparation of Citalopram.
AU2001242298A1 (en) 2000-03-13 2001-09-24 H Lunbeck A/S Method for the preparation of citalopram
DE60101786T2 (en) 2000-03-14 2004-07-15 H. Lundbeck A/S, Valby METHOD FOR PRODUCING CITALOPRAM
US6339182B1 (en) * 2000-06-20 2002-01-15 Chevron U.S.A. Inc. Separation of olefins from paraffins using ionic liquid solutions
CN100457747C (en) * 2006-11-21 2009-02-04 浙江大学 Preparation process of key intermediate 5-cyanphthalide of antidepressant drug citalopram
CN103127815B (en) * 2013-02-19 2015-10-28 浙江大学 A kind of method utilizing the effect of halogen sulphur to improve sulfur dioxide trapping performance

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136193A (en) * 1976-01-14 1979-01-23 Kefalas A/S Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (en) 1965-03-18
US4665181A (en) * 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
US5296507A (en) 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
JPH0881456A (en) * 1994-09-14 1996-03-26 Sumitomo Chem Co Ltd Process for producing 1,1,3,3-tetrachloro-1,3-dihydroisobenzofuran derivative
DE19626659A1 (en) 1996-07-03 1998-01-08 Basf Ag Process for the production of phthalides
DE19627697A1 (en) 1996-07-10 1998-01-15 Basf Ag Process for the production of phthalides
DK1015416T3 (en) 1997-07-08 2001-11-05 Lundbeck & Co As H Process for the preparation of citalopram
UA62985C2 (en) 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
AU738359B2 (en) 1997-11-11 2001-09-13 H. Lundbeck A/S Method for the preparation of citalopram
EA002977B1 (en) 1998-10-20 2002-12-26 Х.Лундбекк А/С Method for the preparation of citalopram
TR200101796T2 (en) 1998-12-23 2001-11-21 H. Lundbeck A/S 5-Method for the preparation of cyanophthalitis
AR022329A1 (en) 1999-01-29 2002-09-04 Lundbeck & Co As H METHOD FOR THE PREPARATION OF 5-CYANOFTALIDE
NZ514671A (en) 1999-04-14 2003-10-31 H Method for the preparation of citalopram
ITMI991579A1 (en) 1999-06-25 2001-01-15 Lundbeck & Co As H METHOD FOR THE PREPARATION OF CITALOPRAM
ITMI991581A1 (en) 1999-06-25 2001-01-15 Lundbeck & Co As H METHOD FOR THE PREPARATION OF CITALOPRAM
AU742554B2 (en) 1999-10-25 2002-01-03 H. Lundbeck A/S Method for the preparation of citalopram
AR026063A1 (en) 1999-11-01 2002-12-26 Lundbeck & Co As H METHOD FOR THE PREPARATION OF 5-CARBOXIFTALIDA.
US6310222B1 (en) 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
DE69915713T2 (en) 1999-12-28 2005-03-03 H. Lundbeck A/S PROCESS FOR THE PREPARATION OF CITALOPRAM
SK286879B6 (en) 2000-01-14 2009-07-06 H. Lundbeck A/S Method for the preparation of 5-cyanophthalide
IES20010143A2 (en) 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
FR2805812A1 (en) 2000-02-24 2001-09-07 Lundbeck & Co As H PROCESS FOR THE PREPARATION OF CITALOPRAM
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
IL144817A0 (en) 2000-08-18 2002-06-30 Lundbeck & Co As H Method for the preparation of citalopram
CN1282648C (en) 2000-12-22 2006-11-01 H·隆德贝克有限公司 Method for preparation of pure citalopram
KR100430746B1 (en) 2000-12-28 2004-05-10 하. 룬트벡 아크티에 셀스카브 Process for the preparation of pure citalopram

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136193A (en) * 1976-01-14 1979-01-23 Kefalas A/S Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849749B2 (en) 1999-04-14 2005-02-01 H. Lundbeck A/S Method for the preparation of citalopram
US20050124817A1 (en) * 1999-04-14 2005-06-09 Hans Petersen Method for the preparation of citalopram
US7030252B2 (en) 1999-04-14 2006-04-18 H. Lundbeck A/S Method for the preparation of citalopram
US6768011B2 (en) 2000-03-03 2004-07-27 H. Lundbeck A/S Method for the preparation of citalopram
US20050020670A1 (en) * 2000-03-13 2005-01-27 H. Lundbeck A/S Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofuran
US6660873B2 (en) 2000-05-12 2003-12-09 H. Lundbeck A/S Method for the preparation of citalopram
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate

Also Published As

Publication number Publication date
HUP0203840A2 (en) 2003-05-28
NO20023150L (en) 2002-06-28
US7271273B2 (en) 2007-09-18
TR200201688T2 (en) 2002-11-21
AU1858400A (en) 2001-07-16
CN1211377C (en) 2005-07-20
CA2395733A1 (en) 2001-07-12
JP2003519218A (en) 2003-06-17
EA200200728A1 (en) 2002-12-26
MXPA02006504A (en) 2002-12-09
UA73336C2 (en) 2005-07-15
EA004055B1 (en) 2003-12-25
DE69912652D1 (en) 2003-12-11
NO328359B1 (en) 2010-02-01
PL355531A1 (en) 2004-05-04
PT1246813E (en) 2004-02-27
DE69912652T2 (en) 2004-06-09
ES2207312T3 (en) 2004-05-16
IS6433A (en) 2002-06-19
HRP20020633A2 (en) 2004-12-31
PL198803B1 (en) 2008-07-31
SK11052002A3 (en) 2003-01-09
CN1391566A (en) 2003-01-15
NO20023150D0 (en) 2002-06-28
EP1246813B1 (en) 2003-11-05
IL150367A (en) 2010-06-16
HK1052512B (en) 2006-03-03
ATE253568T1 (en) 2003-11-15
HUP0203840A3 (en) 2005-02-28
US20060079700A1 (en) 2006-04-13
SI1246813T1 (en) 2004-08-31
CA2395733C (en) 2007-03-20
CZ20022627A3 (en) 2002-10-16
EP1246813A1 (en) 2002-10-09
IL150367A0 (en) 2002-12-01
WO2001049672A1 (en) 2001-07-12
IS2167B (en) 2006-11-15
DK1246813T3 (en) 2004-03-01
KR20020073495A (en) 2002-09-26
BR9917604A (en) 2002-12-31
KR100653141B1 (en) 2006-12-01
HK1052512A1 (en) 2003-09-19

Similar Documents

Publication Publication Date Title
US6750358B2 (en) Method for the preparation of citalopram
KR100491368B1 (en) Method for the preparation of citalopram
US7271273B2 (en) Method for the preparation of citalopram
ZA200205023B (en) Method for preparation of citalopram.
BG65515B1 (en) Method for the preparation of 5-cyanophthalide

Legal Events

Date Code Title Description
AS Assignment

Owner name: H. LUNDBECK A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PETERSEN, HANS;ROCK, MICHAEL HAROLD;REEL/FRAME:013230/0543;SIGNING DATES FROM 20020729 TO 20020730

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION